Optimal interval for routine cytology screening in the United States

Por Kim, Jane J., Sharma, Monisha, Ortendahl, Jesse
Publicado em 2013

Cost-Effectiveness of HPV Vaccination and Cervical Cancer Screening in Women over Age 30 in the United States

Por Kim, Jane J., Ortendahl, Jesse, Goldie, Sue J.
Publicado em 2009

Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line anti...

Por Juday, Timothy, Correll, Todd, Anene, Ayanna, Broder, Michael S, Ortendahl, Jesse, Bentley, Tanya
Publicado em 2013

Trade-offs in Cervical Cancer Prevention: Balancing Benefits and Risks

Por Stout, Natasha K., Goldhaber-Fiebert, Jeremy D., Ortendahl, Jesse D., Goldie, Sue J.
Publicado em 2008

Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals

Por Ortendahl, Jesse D, Pulgar, Sonia J, Mirakhur, Beloo, Cox, David, Bentley, Tanya GK, Phan, Alexandria T
Publicado no Clinicoecon Outcomes Res (2017)

Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination

Por Goldhaber-Fiebert, Jeremy D, Stout, Natasha K, Ortendahl, Jesse, Kuntz, Karen M, Goldie, Sue J, Salomon, Joshua A
Publicado em 2007

HEALTH AND ECONOMIC IMPACT OF HPV 16/18 VACCINATION AND CERVICAL CANCER SCREENING IN EASTERN AFRICA

Por Campos, Nicole G., Kim, Jane J., Castle, Philip E., Ortendahl, Jesse D., O'Shea, Meredith, Diaz, Mireia, Goldie, Sue J.
Publicado em 2011